தலைமை நிதி அதிகாரி கார்ஸ்டன் மஂக் நட்‌ஸெந் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Feb 4, 2021 8:59am
Novo Nordisk is in the process of completing a massive active pharmaceutical ingredient plant in North Carolina and plans to add more capacity as its oral drug development advances. (Artist rendering courtesy of Novo Nordisk)
Novo Nordisk is off and running with its launch for oral semaglutide, a Type 2 diabetes med carrying blockbuster expectations. But the company also sees potential new uses for its oral delivery platform, and it s bolstering its manufacturing network to support its forays in that direction.
The Danish drugmaker said Wednesday it expects to spend around 8 billion Danish kroner ($1.3 billion) on capital projects in 2021 as it gears up to add capacity for active pharmaceutical ingredients. That spending will help advance its oral drug delivery work, Chief Financial Officer Karsten Munk Knudsen said on a conference call with analysts.   ....

North Carolina , United States , Karsten Munk Knudsen , Krogsgaard Thomsen , Novo Nordisk , Chief Financial Officer Karsten Munk Knudsen , Mads Krogsgaard Thomsen , வடக்கு கரோலினா , ஒன்றுபட்டது மாநிலங்களில் , கார்ஸ்டன் மஂக் நட்‌ஸெந் , தலைமை நிதி அதிகாரி கார்ஸ்டன் மஂக் நட்‌ஸெந் ,